Next Article in Journal
6-[(2S,3R)-3-(2,4-Difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl]-5-fluoropyrimidine-4-carbaldehyde
Next Article in Special Issue
tert-Butyl (E)-3-oxo-2-(3-oxoisobenzofuran-1(3H)-ylidene)butanoate
Previous Article in Journal
2-[2,6-Diisopropylphenyl]-4-phenyl-5H-5,9b[1′,2′]-benzonaphtho[1,2-b]pyrrol-2-ium Tetrafluoroborate
Previous Article in Special Issue
4,4′-Difluoro-[3,3′-bi(1,2,5-oxadiazole)] 2,2′-Dioxide
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

New 2-(2,4-Dihydroxyphenyl)benzimidazolines

1
Department of Organic Chemistry, Faculty of Chemistry, University of Plovdiv “Paisii Hilendarski”, Tzar Asen Str. 24, 4000 Plovdiv, Bulgaria
2
Chemistry of Tobacco and Tobacco Smoke, Tobacco and Tobacco Products Institute, Agricultural Academy, Markovo, 4108 Plovdiv, Bulgaria
*
Author to whom correspondence should be addressed.
Molbank 2023, 2023(1), M1602; https://doi.org/10.3390/M1602
Submission received: 20 February 2023 / Revised: 6 March 2023 / Accepted: 7 March 2023 / Published: 10 March 2023
(This article belongs to the Collection Heterocycle Reactions)

Abstract

:
New 2-(2,4-dihydroxyphenyl)benzimidazolines are synthesized in an easily accessible approach. The method is based on the reaction of resorcinol with in situ-formed electrophilic N-ethoxycarbonylbenzimidazolium reagents. The structure of the two newly formed products was spectrally characterized by 1D and 2D NMR, IR, and MS spectral analyses.

Graphical Abstract

1. Introduction

Derivatives of 2-substituted benzimidazole play a useful structural motif for the development of molecules with pharmaceutical interests [1,2,3]. The benzimidazole skeleton containing an aryl substituent at C-2 is part of an important class of bicyclic privileged substructures with powerful effectiveness as enzyme inhibitors [4,5], antimicrobials [6], antiprotozoal agents [7], antioxidants [8], with cytotoxic activity [9,10,11], luminescent [12] and fluorescent materials [13,14], etc.
On the other hand, phenolic compounds are of exceptional interest for organic synthesis, including their application for the development of new medicinals [15]. Many of them have proven antioxidant activity and application for the treatment of various cardiovascular, neurological, and cancer diseases [16]. Some phenols (such as resorcinol) occur in low concentrations as free phenolic substances in plants [17]. In addition, the possibility of the application of resorcinol in antimicrobial textiles was recently reported [18], as well as the immunomodulatory potential of new benzothiazole–resorcinol hybrids [19].
In this regard, a series of condensation reactions of 1,2-phenylenediamine and aldehyde using the following catalysts: cobalt(II) hydroxide [20], sodium dithionite [21], sodium disulfite [22], sodium hydrogen sulfite in ethanol [23], and sodium metabisulfite [24] have been recently published for the synthesis of 2-(2,4-dihydroxyphenyl)benzimidazoles. Nevertheless, synthetic data for the modification of benzimidazole ring with resorcinol by an α-amidoalkylation reaction were still not found in the literature.
Reactions of α-amidoalkylation play an important role in organic synthesis for the building of carbon–carbon or carbon–heteroatom bonds. This method has some advantages over the known Mannich reaction. A wide range of nitrogen containing amidoalkylation precursors are used to generate N-acylimines or N-acyliminium ions as highly reactive intermediates [25]. N-acyliazolinium salts prepared in situ have been used in reactions with 2-silylazoles [26], allyltributyltin compounds [27], silyl enol ethers [28], and organoindium reagents [29]. The current direction of our scientific group is developing an accessible approach for the amidoalkylation of various heterocycles. In this context, we recently reported 1-pot synthesis of various 2-hydroxyphenyl-benzothiazolines as potential antimicrobials active against Bacillus licheniformis MIC = 0.0008–0.0500 mg/mL and Staphylococcus aureus MIC = 0.0016–0.0125 mg/mL, as well as new quercetin hybrids with radical scavenging profile with varied IC50 values in the range of 6.17 ± 0.3–7.26 ± 0.3 µM measured with DPPH assay, and 49.8 ± 3.5–62.4 ± 3.5 µM with ABTS assay [30,31].
The aim of this study is to apply the same manner for the modification of the benzimidazole ring with resorcinol.

2. Results and Discussion

Motivated by the previous successful work for the synthesis of quercetin-containing benzimidazole hybrids [31], here, we report our current investigations on the application of adducts (4) obtained from benzimidazole and 5,6-dimethylbenzimidazole (1,2) with ethyl chloroformate for the amidoalkylation of resorcinol. The above-mentioned reactions lead to products (5a,b) according to Scheme 1.
The reaction conditions, including the ratio of the reagents and time, are presented in Table 1.
The reactions were successfully completed under room temperature (20–25 °C) for 5 h. It was found that dichloromethane is a suitable solvent for carrying out the reactions. The best yields of products (89%, 5a) and (92%, 5b, Table 1) were obtained with the continuous addition of 2 equivalents of resorcinol dissolved in 3 milliliters of acetonitrile. In the course of the reactions, triethylamine was added as a hydrochloric scavenger. Table 1 indicates the reaction conditions under which the monosubstituted products were obtained with the highest yields. It is found that the yield scope depended on the stability of the products in an acidic medium. The unexpected mixture of compounds (monitored by TLC) was observed using an equimolar ratio of starting reagents according to our previously published study [30]. For the reactions of N-acylation with benzimidazole and 5,6-dimethylbenzimidazole, the presence of Et3N as a hydrochloric scavenger was required and established at 0 °C.
The products are successfully crystallized using a mixture of petroleum/diethyl ether. Relatively pure samples of monosubstituted benzimidazolines were isolated by column chromatography on silica gel.
The structure of products (5a,b) was confirmed by 1D and 2D NMR, IR, and MS spectral data. To average out the rotamers observed in N,N-diethoxycarbonyl-benzimidazolines reaching adequate assignment of peaks and structure determination, the NMR spectra were measured at 80 °C in DMSO-d6. The 1H-NMR spectra of the analyzed compounds indicate an easily recognizable set of quartets about δ = 4.10 ppm and triplets about δ = 1.15 ppm for the protons from 2 methyl- and methylene- groups part of diethoxycarbonyl fragments. Furthermore, singlets for the proton on sp3- C-2 atom in benzimidazole rings were observed in the range of δ = 6.90–6.93 ppm. The 1H-, 13C-HSQC measurements proved the exact location of these characteristic signals, including the position of substitution. Consequently, the protons from OH groups are detected as a brought singlet at 9.93 ppm for 5a and 9.04 ppm for 5b. The signals of 13C-NMR spectra comply with all carbon atoms from the expected structures. Analyzing the IR spectra also gives us enough evidence for the presence of the expected structural fragments and functional groups (see fully associated IR bands in the Materials and Methods section).
The original 1D and 2D NMR, IR, and MS spectra of the molecules are available in the Supplementary Materials Section (S1).

3. Materials and Methods

Benzimidazole [CAS No. 51-17-2], 5,6-dimethylbenzimidazole [CAS No. 582-60-5], triethylamine [CAS No. 121-44-8], ethyl chloroformate [CAS No. 541-41-3], resorcinol [CAS No. 108-46-3], and the dry organic solvents were purchased from Sigma-Aldrich, Merck (Darmstadt, Germany).
Melting points were measured on a Kruss M5000 melting point meter (A.Krüss Optronic GmbH, Hamburg, Germany). IR spectra were measured on an ALPHA II FT-IR spectrometer (Bruker Optics GmbH, Ettlingen, Germany). High-resolution mass spectral measurements were performed on a Bruker mass spectrometer. 1H-, 13C-NMR spectra were measured on Bruker Avance NEO AV400 spectrometer (Bruker, Billerica, MA, USA) at BAS-IOCCP—Sofia, and chemical shifts (δ, ppm) are downfield from TMS. TLC was done on precoated 0.2 mm Merck silica gel 60 plates. Silica gel was used for column chromatography.

Synthesis of 2-(2,4-Dihydroxyphenyl)benzimidazolines (5a,b), General Procedure

The ethyl chloroformate (1.2 mmol, 0.12 mL) was added dropwise to a magnetically stirred solution of benzimidazole (1 mmol, 0.118 g) or 5,6-dimethylbenzimidazole (1 mmol, 0.146 g) and triethylamine (1 mmol, 0.14 mL) in 10 mL dichloromethane at 0 °C. After 20 min, another 1.2 mmol ethyl chloroformate was added, and the reaction mixture was transferred at room temperature (20–25 °C) for 60 min. Then, resorcinol (0.220 g, 2 mmol) dissolved in 3 mL acetonitrile was added dropwise to the reaction mixture for the course of 30 min. Thereafter, triethylamine (1 mmol, 0.14 mL) dissolved in dichloromethane (5 mL) was sequentially added dropwise to the reaction mixture for a period of 60 min as a hydrochloric scavenger. Then, the reaction was continued under the conditions described in Table 1. After completion of the reaction (monitored by TLC), the reaction mixture was dissolved in chloroform (30 mL) and washed successively with 1% HCl (40 mL) and water (40 mL). The organic layer was dried over Na2SO4, and the solvent was evaporated under reduced pressure. The products were isolated by crystallization with mixtures of petroleum/diethyl ether. Relatively pure samples (TLC) are obtained with filtration through short-column chromatography on silica gel.
Molbank 2023 m1602 i001
Compound 5a (Diethyl 2-(2,4-dihydroxyphenyl)-1H-benzo[d]imidazole-1,3(2H)-dicarboxylate) was a white powder isolated by crystallization with a mixture of petroleum/diethyl ether 4:1, Rf = 0.3 (petroleum:diethyl ether 1:2). Its yield: (0.33 g, 89%), m.p.: 204–206 °C, accompanied by decomposition and darkening;
1H-NMR (400 MHz, 80 °C, DMSO-d6, δ ppm, J Hz): 9.07 (s, 2H, 2x-OH), 7.59 (dd, J = 5.9, 3.3 Hz, 2H, 2x-CH-benzimidazole), 6.99 (dd, J = 5.9, 3.4 Hz, 2H, 2x-CH-benzimidazole), 6.93 (s, 1H, -*CH), 6.89 (d, J = 8.4 Hz, 1H, -CH-resorcinol), 6.23 (d, J = 2.4 Hz, 1H, -CH-resorcinol), 6.17 (dd, J = 8.4, 2.5 Hz, 1H, -CH-resorcinol), 4.10 (q, J = 7.0 Hz, 4H, 2x-COCH2CH3), 1.15 (t, J = 7.0 Hz, 6H, 2x-COCH2CH3);
13C-NMR (101 MHz, 80 °C, DMSO-d6, δ ppm, J Hz): 159.2(-C-OH), 156.9 (-C-OH), 151.3 (2x-COCH2CH3), 133.2 (-2xC-benzimidazole), 129.8 (-CH), 123.0 (-CH), 116.9 (-CH), 113.6 (-CH), 106.7 (-CH), 103.2 (-CH), 74.5 (-*CH), 61.8 (2x-COCH2CH3), 14.4 (2x-COCH2CH3);
HRMS m/z (ESI): calcd for C19H19N2O6 [M-H] 371.1249, found 371.1250;
IR (KBr, cm−1): 3380 (O-H), 2982, 2931, 2906 (Csp3-H), 1695 (C=O), 1594, 1504, 1416 (C=C), 1383 (O-H), 1317 (C-N), 1285 (C-O-C), 1203 (C-O), 1184 (C-CO-C), 1096, 1049, 1020 (C-N).
Molbank 2023 m1602 i002
Compound 5b (Diethyl 2-(2,4-dihydroxyphenyl)-5,6-dimethyl-1H-benzo[d]imidazole-1,3(2H)-dicarboxylate) was a white powder isolated by crystallization with a mixture of petroleum/diethyl ether 8:1, Rf = 0.75 (diethyl ether). Its yield: (0.37 g, 92%), m.p.: 217–219 °C, accompanied by decomposition and darkening;
1H-NMR (400 MHz, 80 °C, DMSO-d6, δ ppm, J Hz): 9.04 (s, 2H, 2x-OH), 7.39 (s, 2H, 2x-CH-5,6-dimethylbenzimidazole), 6.90 (s, 1H, -*CH), 6.85 (d, J = 8.4 Hz, 1H, -CH-resorcinol), 6.22 (d, J = 2.3 Hz, 1H, -CH-resorcinol), 6.15 (dd, J = 8.4, 2.4 Hz, 1H, -CH-resorcinol), 4.08 (q, J = 7.1 Hz, 4H, 2x-COCH2CH3), 2.21 (s, 6H, 2x-CH3), 1.14 (t, J = 7.1 Hz, 6H, 2x-COCH2CH3);
13C-NMR (101 MHz, 80 °C, DMSO-d6, δ ppm, J Hz): 159.1 (-C-OH), 156.8 (-C-OH), 151.2 (2x-COCH2CH3), 131.1 (-2C-5,6-dimethylbenzimidazole), 130.3 (-2C-5,6-dimethylbenzimidazole), 129.4 (-CH), 117.1 (-CH), 115.0 (-CH), 106.7 (-CH), 103.2 (-CH), 74.2 (-*CH), 61.7 (2x-COCH2CH3), 19.8 (2x-CH3), 14.4 (2x-COCH2CH3);
HRMS m/z (ESI): calcd for C21H23N2O6 [M-H] 399.1562, found 399.1564;
IR (KBr, cm−1): 3345 (O-H), 2980, 2935, 2865 (Csp3-H), 1697 (C=O), 1611, 1516, 1461 (C=C), 1383 (O-H), 1320 (C-N), 1297 (C-O-C), 1260 (C-O), 1162 (C-CO-C), 1100, 1076, 1026 (C-N).

4. Conclusions

We have successfully synthesized two new 2-(2,4-dihydroxyphenyl) benzimidazolines, employing an efficient high-yielding approach. The applied N-acylliminium reagents formed in situ from benzimidazole or 5,6-dimethylbenzimidazole and ethyl chlorformate react with resorcinol, providing access to N,N-diethoxycarbonyl-benzimidazolines containing resorcinol fragment in the moiety. The obtained products are interesting because of their potential biological activities.

Supplementary Materials

The following supporting information can be downloaded online. S1.pdf—processed 1H-, 13C-NMR, HSQC, IR and MS spectra. 2-(2,4-dihydroxyphenyl)benzimidazolines 5a,b mol files.

Author Contributions

Manuscript writing: Y.S.; revising and final English check: S.S.-A.; chemical synthesis: D.K., M.B. and Y.S.; spectral analysis: Y.S. and M.B. All authors have read and agreed to the published version of the manuscript.

Funding

The present study was financially supported by the National Science Fund of the Bulgarian Ministry of Education and Science (grant number KΠ-06-M59/5-2021) and by the Bulgarian Ministry of Education and Science under the National Program “Young Scientists and Postdoctoral Students—2”.

Data Availability Statement

The data presented in this study are available in this article and supporting information.

Acknowledgments

We gratefully acknowledge the operational program “Science and education for smart growth” 2014–2020 (grant number BG05M2OP001-1.002-0005-c01), Personalized Innovative Medicine competence centre (PERIMED).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Karthikeyan, C.; Solomon, V.R.; Lee, H.; Trivedi, P. Synthesis and biological evaluation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl esters as potent anti-breast cancer agents. Arab. J. Chem. 2017, 10, 1788–1794. [Google Scholar] [CrossRef] [Green Version]
  2. Gulcan, H.O.; Mavideniz, A.; Sahin, M.F.; Orhan, I.E. Benzimidazole-derived compounds designed for different targets of Alzheimer’s disease. Curr. Med. Chem. 2019, 26, 3260–3278. [Google Scholar] [CrossRef]
  3. Lee, Y.T.; Tan, Y.J.; Oon, C.E. Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharm. Sin. B 2022, 13, 478–497. [Google Scholar] [CrossRef] [PubMed]
  4. Bino, A.; Baldisserotto, A.; Scalambra, E.; Dissette, V.; Vedaldi, D.E.; Salvador, A.; Durini, E.; Manfredini, S.; Vertuani, S. Design, synthesis and biological evaluation of novel hydroxy-phenyl-1H-benzimidazoles as radical scavengers and UV-protective agents. J. Enzyme Inhib. Med. Chem. 2017, 32, 527–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Matysiak, J.; Skrzypek, A.; Karpinska, M.; Czarnecka, K.; Szymanski, P.; Bajda, M.; Niewiadomy, A. Biological evaluation, molecular docking, and SAR studies of novel 2-(2,4-dihydroxyphenyl)-1H-benzimidazole analogues. Biomolecules 2019, 9, 870. [Google Scholar] [CrossRef] [Green Version]
  6. Padalkar, V.S.; Borse, B.N.; Gupta, V.D.; Phatangare, K.R.; Patil, V.S.; Umape, P.G.; Sekar, N. Synthesis and antimicrobial activity of novel 2-substituted benzimidazole, benzoxazole and benzothiazole derivatives. Arab. J. Chem. 2016, 9, 1125–1130. [Google Scholar] [CrossRef] [Green Version]
  7. Ismail, M.A.; Brun, R.; Wenzler, T.; Tanious, F.A.; Wilson, W.D.; Boykin, D.W. Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg. Med. Chem. 2004, 12, 5405–5413. [Google Scholar] [CrossRef]
  8. Racané, L.; Cindrić, M.; Perin, N.; Roškarić, P.; Starčević, K.; Mašek, T.; Maurić, M.; Dogan, J.; Karminski-Zamola, G. Synthesis and antioxidative potency of novel amidino substituted benzimidazole and benzothiazole derivatives. Croat. Chem. Acta 2017, 90, 187–195. [Google Scholar] [CrossRef]
  9. Karpińka, M.M.; Matysiak, J.; Niewiadomy, A. Synthesis of novel 4-(1H-benzimidazol-2-yl)benzene-1,3-diols and their cytotoxic activity against human cancer cell lines. Arch. Pharm. Res. 2011, 34, 1639–1647. [Google Scholar] [CrossRef] [PubMed]
  10. Gellis, A.; Kovacic, H.; Boufatah, N.; Vanelle, P. Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents. Eur. J. Med. Chem. 2008, 43, 1858–1864. [Google Scholar] [CrossRef]
  11. Matysiak, J.; Opolski, A. Synthesis and antiproliferative activity of N-substituted 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4-thia-diazoles. Bioorg. Med. Chem. 2006, 14, 4483–4489. [Google Scholar] [CrossRef]
  12. Kiprof, P.; Carlson, J.C.; Anderson, D.R.; Nemykin, V.N. Systematic color tuning of a family of luminescent azole-based organoboron compounds suitable for OLED applications. Dalton Trans. 2013, 42, 15120–15132. [Google Scholar] [CrossRef] [PubMed]
  13. Patil, V.S.; Padalkar, V.S.; Tathe, A.B.; Gupta, V.D.; Sekar, N. Synthesis, photo-physical and DFT studies of ESIPT inspired novel 2-(2′,4′-dihydroxyphenyl) benzimidazole, benzoxazole and benzothiazole. J. Fluoresc. 2013, 23, 1019–1029. [Google Scholar] [CrossRef] [PubMed]
  14. Padalkar, V.S.; Tathe, A.; Gupta, V.D.; Patil, V.S.; Phatangare, K.; Sekar, N. Synthesis and photo-physical characteristics of ESIPT inspired 2-substituted benzimidazole, benzoxazole and benzothiazole fluorescent derivatives. J. Fluoresc. 2012, 22, 311–322. [Google Scholar] [CrossRef]
  15. Roush, W.R. Total synthesis of biologically active natural products. J. Am. Chem. Soc. 2008, 130, 6654–6656. [Google Scholar] [CrossRef] [Green Version]
  16. Minatel, I.O.; Borges, C.V.; Ferreira, M.I.; Gomez, H.A.G.; Chen, C.Y.O.; Lima, G.P.P. Phenolic Compounds: Functional Properties, Impact of Processing and Bioavailability. In Phenolic Compounds—Biological Activity; InTech: London, UK, 2017; Chapter 1. [Google Scholar] [CrossRef] [Green Version]
  17. Dewick, P.M. Medicinal Natural Products: A Biosynthetic Approach, 3rd ed.; John Wiley & Sons: Nottingham, UK, 2009; p. 53. [Google Scholar]
  18. Alihosseini, F. Plant-based compounds for antimicrobial textiles. In Antimicrobial Textiles; Elsevier Inc.: Amsterdam, The Netherlands, 2016; pp. 155–195. [Google Scholar] [CrossRef]
  19. Khan, K.M.; Mesaik, M.A.; Abdalla, O.M.; Rahim, F.; Soomro, S.; Halim, S.A.; Mustafa, G.; Ambreen, N.; Khalid, A.S.; Taha, M.; et al. The immunomodulation potential of the synthetic derivatives of benzothiazoles: Implications in immune system disorders through in vitro and in silico studies. Bioorg. Chem. 2016, 64, 21–28. [Google Scholar] [CrossRef]
  20. Chari, M.A.; Shobha, D.; Sasaki, T. Room temperature synthesis of benzimidazole derivatives using reusable cobalt hydroxide (II) and cobalt oxide (II) as efficient solid catalysts. Tetrahedron Lett. 2011, 52, 5575–5580. [Google Scholar] [CrossRef]
  21. Han, F.; Zhang, X.; Zhang, J.; Wei, Y.; Zhang, X.; Huang, W.; Xu, H. 3D-Encapsulated iridium-complexed nanophosphors for highly efficient host-free organic light-emitting diodes. Chem. Commun. 2016, 52, 5183–5186. [Google Scholar] [CrossRef] [PubMed]
  22. Khan, K.M.; Khan, M.; Ambreen, N.; Rahim, F.; Naureen, S.; Perveen, S.; Choudhary, M.L.; Voelter, W. Synthesis and β-Glucuronidase Inhibitory Potential of Benzimidazole Derivatives. J. Med. Chem. 2012, 8, 421–427. [Google Scholar] [CrossRef]
  23. Castillo-García, A.A.; González-Sebastián, L.; Lomas-Romero, L.; Hernandez-Ortega, S.; Toscano, R.A.; Morales-Morales, D. Novel meta-benzothiazole and benzimidazole functionalised POCOP-Ni(ii) pincer complexes as efficient catalysts in the production of diarylketones. New J. Chem. 2021, 45, 10204–10216. [Google Scholar] [CrossRef]
  24. Shi, Y.; Meng, X.; Yang, H.; Song, L.; Liu, S.; Xu, A.; Chen, Z.; Huang, W.; Zhao, Q. Lysosome-specific sensing and imaging of pH variations in vitro and in vivo utilizing a near-infrared boron complex. J. Mater. Chem. B 2019, 7, 3569–3575. [Google Scholar] [CrossRef]
  25. Mazurkiewicz, R.; Październiok-Holewa, A.; Adamek, J.; Zielińska, K. α-Amidoalkylating agents: Structure, synthesis, reactivity and application. Adv. Heterocycl. Chem. 2014, 111, 43–93. [Google Scholar] [CrossRef]
  26. Dondoni, A.; Dall’Occo, T.; Galliani, G.; Mastellari, A.; Medici, A. Addition of 2-silylazoles to heteroaryl cations. Synthesis of unsymmetrical azadiaryls. Tetrahedron Lett. 1984, 25, 3637–3640. [Google Scholar] [CrossRef]
  27. Itoh, T.; Hasegawa, H.; Nagata, K.; Ohsawa, A. Allylation of Azoles with Allyltributyltin via Unstable N-(Alkoxycarbonyl)azlium Salts. J. Org. Chem. 1994, 59, 1319–1325. [Google Scholar] [CrossRef]
  28. Itoh, T.; Miyazaki, M.; Nagata, K.; Ohsawa, A. Addition Reaction of Imidazoles and Thiazoles with Silyl Enol Ethers in the Presence of Alkyl Chloroformate. Tetrahedron Lett. 2000, 56, 4383–4395. [Google Scholar] [CrossRef]
  29. Beveridge, R.E.; Black, D.A.; Arndtsen, B.A. Copper-Catalyzed multicomponent coupling of organoindium reagents with nitrogen-containing aromatic heterocycles. Eur. J. Org. Chem. 2010, 19, 3650–3656. [Google Scholar] [CrossRef]
  30. Stremski, Y.; Kirkova, D.; Statkova-Abeghe, S.; Angelov, P.; Ivanov, I.; Georgiev, D. Synthesis and antibacterial activity of hydroxylated 2-arylbenzothiazole derivatives. Synth. Commun. 2020, 50, 3007–3015. [Google Scholar] [CrossRef]
  31. Kirkova, D.; Stremski, Y.; Statkova-Abeghe, S.; Docheva, M. Quercetin Hybrids-Synthesis, Spectral Characterization and Radical Scavenging Potential. Molbank 2022, 2022, M1329. [Google Scholar] [CrossRef]
Scheme 1. Synthesis of N,N-diethoxycarbonyl-2-(2,4-dihydroxyphenyl)benzimidazolines (5a,b) by reaction of α-amidoalkylation; (i) CH2Cl2, Et3N, 0 °C, 20 min.; (ii) ClCOOEt, r.t., 60 min.; and (iii) Resorcinol dissolved in CH3CN, Et3N, r.t., 5 h.
Scheme 1. Synthesis of N,N-diethoxycarbonyl-2-(2,4-dihydroxyphenyl)benzimidazolines (5a,b) by reaction of α-amidoalkylation; (i) CH2Cl2, Et3N, 0 °C, 20 min.; (ii) ClCOOEt, r.t., 60 min.; and (iii) Resorcinol dissolved in CH3CN, Et3N, r.t., 5 h.
Molbank 2023 m1602 sch001
Table 1. The ratio of the reagents, reaction time and yields of 5a and 5b, Scheme 1 (iii).
Table 1. The ratio of the reagents, reaction time and yields of 5a and 5b, Scheme 1 (iii).
Product 5RRatio *Time, hYield, %
aH1:12450
aH1:2589
bMe1:12456
bMe1:2592
* ratio of N,N-diethoxycarbonylbenzimidazolium ions: resorcinol.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Stremski, Y.; Bachvarova, M.; Kirkova, D.; Statkova-Abeghe, S. New 2-(2,4-Dihydroxyphenyl)benzimidazolines. Molbank 2023, 2023, M1602. https://doi.org/10.3390/M1602

AMA Style

Stremski Y, Bachvarova M, Kirkova D, Statkova-Abeghe S. New 2-(2,4-Dihydroxyphenyl)benzimidazolines. Molbank. 2023; 2023(1):M1602. https://doi.org/10.3390/M1602

Chicago/Turabian Style

Stremski, Yordan, Maria Bachvarova, Desislava Kirkova, and Stela Statkova-Abeghe. 2023. "New 2-(2,4-Dihydroxyphenyl)benzimidazolines" Molbank 2023, no. 1: M1602. https://doi.org/10.3390/M1602

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop